Abstract

Cagrilintide is a long-acting amylin analog peptide engineered to mimic the function of amylin, a hormone normally released alongside insulin by pancreatic beta cells. Unlike incretin-based therapies, cagrilintide acts primarily on amylin and calcitonin receptors in the brain, offering a complementary pathway for appetite suppression and metabolic regulation.

Molecular Background

Key characteristics of cagrilintide:

• Long-acting amylin analog with extended half-life
• Molecular modifications enhance stability and reduce enzymatic breakdown
• Supports once-weekly subcutaneous administration
• Currently under clinical investigation (not yet FDA-approved)

Mechanism of Action

Cagrilintide operates through distinct pathways from GLP-1 agonists:

• Amylin Receptor Activation: Enhances satiety signaling in the brain
• Calcitonin Receptor: Additional receptor target for appetite modulation
• Gastric Emptying: Prolongs gastric transit time for sustained fullness
• Meal Termination: Promotes earlier cessation of eating
• Craving Reduction: Decreases desire for high-fat and high-sugar foods

Clinical Research Summary

Data from published clinical trials (REDEFINE program):

• Monotherapy: 5-10% body weight loss compared to placebo
• Combination with Semaglutide: Up to 15% weight reduction
• Secondary Outcomes: Reduced waist circumference, visceral fat mass, and appetite scores
• Adherence: Once-weekly dosing improves patient compliance

Synergy with GLP-1 Agonists

When paired with semaglutide, cagrilintide creates a dual-pathway approach targeting both incretin and amylin networks. Clinical trials show enhanced outcomes when both peptides are combined:

• Greater total weight loss than either peptide alone
• Improved satiety and reduced food cravings
• Potential solution for GLP-1-resistant patients
• Overlapping side effects require careful titration

Safety Profile

Common side effects observed in clinical trials:

• Nausea: Mild to moderate, typically during initial titration phase
• Reduced Appetite: Therapeutic goal but may cause inadequate caloric intake
• Bloating: Related to delayed gastric emptying
• Vomiting: Associated with rapid dose escalation

Contraindications

• Medullary Thyroid Carcinoma: Due to calcitonin receptor activity
• MEN2 Syndrome: Receptor overlap with calcitonin pathways
• Severe GI Conditions: Gastroparesis, chronic dysmotility
• Pregnancy/Breastfeeding: Insufficient safety data
• Severe Renal Impairment: eGFR less than 30 mL/min/1.73 m²

Comparison: Cagrilintide vs Semaglutide

Feature	Cagrilintide	Semaglutide
Receptor Target	Amylin/Calcitonin	GLP-1
Administration	Weekly SC injection	Weekly SC injection
FDA Status	Investigational	Approved
Best Use	Combination therapy	Monotherapy or combo

Current Research Status

Cagrilintide remains under clinical investigation and is not yet FDA-approved. Ongoing studies are assessing long-term cardiovascular outcomes, weight loss durability, and real-world adherence. If approved, cagrilintide could become a first-line option in combination with GLP-1 agonists for patients with obesity-related conditions.